Edition:
United Kingdom

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

4.16USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$4.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
176,393
52-wk High
$4.70
52-wk Low
$1.93

Latest Key Developments (Source: Significant Developments)

Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cerus Corp ::CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION.CERUS CORP - UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION.CERUS CORP - EXPECTS FULL YEAR 2017 PRODUCT REVENUE TO BE $43.6 MILLION.CERUS CORPORATION ANNOUNCES PRELIMINARY PRODUCT REVENUE RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017.  Full Article

Cerus Corp reports Q3 loss per share $0.12
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Cerus Corp :Cerus Corp reports third quarter 2017 results.Q3 loss per share $0.12.Q3 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.Cerus Corp - ‍product revenue for q3 of 2017 was $10.8 million, up 6 pct compared to $10.2 million recognized during same period in 2016​.  Full Article

Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cerus Corp :Cerus and Kedrion Biopharma enter distribution agreement for the full INTERCEPT blood system portfolio in Italy.Says ‍entered into an agreement with Kedrion Biopharma to distribute full complement of INTERCEPT blood system products in italy​.Says ‍Kedrion Biopharma will be sole distributor for intercept blood systems in Italy​.Says ‍kedrion Biopharma will have right to distribute INTERCEPT red blood cells following CE mark approval​.  Full Article

Cerus announces agreement with transfusion Center of the Community of Madrid
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Cerus Corp :Cerus announces agreement with transfusion Center of the Community of Madrid.Entered into a supply agreement with Centro de transfusión de la Comunidad de Madrid (CTCM) for intercept blood system for platelets​.  Full Article

Cerus provides U.S. business update
Tuesday, 23 May 2017 

May 23 (Reuters) - Cerus Corp :Cerus provides U.S. business update.A pending platelet additive solution shortage is expected to impact some U.S. blood centers producing intercept platelets.Fresenius Kabi has stated that it is working with its suppliers and FDA to resolve this delay.Cerus Corp says updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to prior range of $43 million to $48 million.Cerus Corp - believe shortage could "adversely" affect intercept platelet production by impacted blood centers through year end.Cerus Corp - received notification last week of a pending U.S. supply shortage of a platelet additive solution manufactured and sold by fresenius kabi.Cerus Corp - pending shortage is due to an unanticipated delay in FDA approval of a plastic component used in manufacture of pas container.  Full Article

Cerus announces first U.S. Blood center customer submits biologics license application
Thursday, 13 Oct 2016 

Cerus Corp : Cerus announces first U.S. Blood center customer submits biologics license application to the FDA to allow for interstate export of intercept platelet components .Cerus -community blood center of Appleton, Wisconsin has submitted first biologics license application to U.S FDA.  Full Article

FDA recommends use of pathogen reduction for universal Zika risk reduction of blood components
Monday, 29 Aug 2016 

Cerus Corp : Fda's new recommendation for universal zika risk reduction of blood components includes use of pathogen reduction .Use of pathogen reduction, such as intercept blood system for platelets and plasma, is specified as an acceptable safety measure.  Full Article

Cerus Q2 loss per share $0.18
Thursday, 4 Aug 2016 

Cerus Corp : Q2 loss per share $0.18 . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Cerus corporation reports second quarter 2016 results . Q2 revenue $9.3 million versus i/b/e/s view $8.9 million . Sees fy 2016 revenue $37 million to $40 million .Fy2016 revenue view $38.7 million -- Thomson Reuters I/B/E/S.  Full Article

Cerus Corp signed multi-year purchase agreement for INTERCEPT Blood System
Tuesday, 9 Feb 2016 

Cerus Corp:Says American Red Cross has signed a multi-year purchase agreement for the INTERCEPT Blood System for platelets and plasma.  Full Article

BRIEF-Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million

* CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION